Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?

Marie-Rose B S CrombagStijn L W KoolenSophie WijngaardMarkus JoergerThomas P C DorloNielka P van ErpRon H J MathijssenJos H BeijnenAlwin D R Huitema

Published in: Pharmaceutical research (2019)

Results from this large retrospective patient cohort do not suggest elderly patients to be at an increased risk of developing paclitaxel-associated neutropenia during the first treatment cycle. Reflexive dose reductions of paclitaxel in elderly patients are unlikely to improve the risk of severe neutropenia and may be deleterious.

Keyphrases

chemotherapy induced
case report
cross sectional
early onset
combination therapy
drug induced